- Home
- IVA vs VACH Comparison
IVA vs VACH Comparison
Compare IVA & VACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- VACH
- Stock Information
- Founded
- IVA 2011
- VACH 2023
- Country
- IVA France
- VACH United States
- Employees
- IVA N/A
- VACH N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- VACH
- Sector
- IVA Health Care
- VACH
- Exchange
- IVA Nasdaq
- VACH NYSE
- Market Cap
- IVA 359.6M
- VACH 324.2M
- IPO Year
- IVA 2020
- VACH 2024
- Fundamental
- Price
- IVA $3.62
- VACH $10.33
- Analyst Decision
- IVA Strong Buy
- VACH
- Analyst Count
- IVA 4
- VACH 0
- Target Price
- IVA $10.50
- VACH N/A
- AVG Volume (30 Days)
- IVA 22.8K
- VACH 32.0K
- Earning Date
- IVA 03-26-2025
- VACH 01-01-0001
- Dividend Yield
- IVA N/A
- VACH N/A
- EPS Growth
- IVA N/A
- VACH N/A
- EPS
- IVA N/A
- VACH 0.30
- Revenue
- IVA $14,591,573.00
- VACH N/A
- Revenue This Year
- IVA $15.38
- VACH N/A
- Revenue Next Year
- IVA $24.22
- VACH N/A
- P/E Ratio
- IVA N/A
- VACH $34.44
- Revenue Growth
- IVA N/A
- VACH N/A
- 52 Week Low
- IVA $1.53
- VACH $9.95
- 52 Week High
- IVA $4.05
- VACH $11.20
- Technical
- Relative Strength Index (RSI)
- IVA 58.88
- VACH N/A
- Support Level
- IVA $3.13
- VACH N/A
- Resistance Level
- IVA $3.54
- VACH N/A
- Average True Range (ATR)
- IVA 0.27
- VACH 0.00
- MACD
- IVA 0.02
- VACH 0.00
- Stochastic Oscillator
- IVA 69.66
- VACH 0.00
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About VACH VOYAGER ACQUISITION CORP.
Voyager Acquisition Corp is a blank check company.